What is the recommended treatment for an uncomplicated urinary tract infection caused by Enterococcus faecalis after nitrofurantoin (Macrobid) failure?

Treatment for Uncomplicated UTI with E. faecalis After Nitrofurantoin Failure

For an uncomplicated UTI caused by E. faecalis that has failed nitrofurantoin therapy, fosfomycin 3 grams as a single oral dose is the recommended first-line alternative, followed by high-dose amoxicillin 500 mg every 8 hours if fosfomycin is unavailable or ineffective.

Primary Treatment Options

The 2022 guidelines for multidrug-resistant organisms provide clear recommendations for enterococcal UTIs 1:

First Choice: Fosfomycin

• Dosing: Single 3-gram oral dose 1
• Rationale: FDA-approved specifically for E. faecalis UTIs 1, with good in vitro activity against vancomycin-resistant enterococci (VRE) and minimal collateral damage
• Evidence: Multiple retrospective studies show promising results for uncomplicated enterococcal UTIs 1
• Strength: Weak recommendation, very low quality evidence (2D) 1

Second Choice: High-Dose Aminopenicillins

• Amoxicillin: 500 mg PO/IV every 8 hours 1
• Ampicillin: 18-30 grams IV daily in divided doses (for severe cases) 1
• Key principle: High urinary concentrations of ampicillin can overcome high MICs even in ampicillin-resistant strains 1
• Evidence: One retrospective study showed 88.1% clinical cure and 86% microbiological eradication in ampicillin-resistant VRE UTIs treated with ampicillin 1
• Recent data: A 2023 study demonstrated aminopenicillins were non-inferior to non-aminopenicillins for enterococcal lower UTIs, with 83.1% clinical success at 14 days 2

Alternative Options if Above Fail

Nitrofurantoin Re-challenge (Different Dosing)

• Dosing: 100 mg PO every 6 hours (not the standard twice-daily Macrobid dosing) 1
• Consideration: Good in vitro activity against VRE 1, though clinical data is limited
• Note: The FDA label indicates nitrofurantoin lacks broader tissue distribution, and many patients are predisposed to persistence or reappearance of bacteriuria 3

Linezolid (Reserve for Complicated Cases)

• Dosing: 600 mg IV or PO every 12 hours 1
• Indication: Should be reserved for confirmed upper tract or bacteremic enterococcal infections 4
• Strength: Strong recommendation for enterococcal infections generally (1C) 1

Clinical Decision Algorithm

1. Confirm true infection vs. colonization - Critical first step 1
2. Obtain urine culture and susceptibilities - Essential for guiding therapy 3
3. First-line: Fosfomycin 3g single dose
4. If fosfomycin unavailable or fails: Amoxicillin 500mg q8h for 5-7 days
5. If symptoms persist after 48-72 hours: Consider culture-directed therapy with linezolid or daptomycin (for complicated/upper tract disease)

Important Caveats

Nitrofurantoin failure considerations:

• The standard Macrobid formulation (100mg twice daily for 5 days) may have failed due to inadequate dosing frequency 5
• E. faecalis is inherently less susceptible to nitrofurantoin than E. coli 3
• Consider whether this represents true treatment failure vs. reinfection

Resistance patterns:

• E. faecalis typically remains ampicillin-susceptible (unlike E. faecium) 6, 1
• Fosfomycin maintains activity even against VRE strains 7, 8
• Recent data shows fosfomycin susceptibility rates of 98% for E. faecalis, including VRE 7

Duration of therapy:

• Uncomplicated cystitis: 3-7 days depending on agent 9
• If symptoms persist beyond expected treatment duration, consider upper tract involvement requiring longer therapy 1

Avoid fluoroquinolones as first-line for simple cystitis due to collateral damage concerns and resistance preservation 5, though they may be considered if other options are unavailable.